Late Effects after Pediatric HSCT: State of the Science, Future Directions

儿科 HSCT 后的后期影响：科学现状、未来方向

• 批准号: 8129911
• 负责人: KEVIN S BAKER
• 金额: $ 1.25万
• 依托单位: NATIONAL CHILDHOOD CANCER FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-08 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8129911
• 关键词: Accounting; Address; Adolescent; Adult; Adverse event; Age; Ally; Area; Biological Markers; Blood; Bone Marrow Transplantation; Cardiac; Cardiovascular system; Cell Transplantation; Cessation of life; Child; Childhood; Children' s Oncology Group; Clinical Trials; Clinical Trials Network; Consensus; Data; Development; Disease; Endocrine; Event; Exposure to; Foundations; Frequencies; Functional disorder; Funding; Future; General Population; Generations; Genetic Predisposition to Disease; Genetic Risk; Goals; Good Clinical Practice; Growth and Development function; Health; Hematopoietic; Hepatic; Hereditary Disease; Human Resources; Immunologic Deficiency Syndromes; Immunosuppression; Individual; Infant; Infection; International; Intervention Trial; Joints; Kidney; Late Effects; Life; Long-Term Survivors; Longitudinal Studies; Lung; Maintenance; Marrow; Methodology; Modality; Modification; Morbidity - disease rate; National Heart, Lung, and Blood Institute; Neurocognitive; North America; Organ; Outcome; Outcome Study; Patients; Pharmaceutical Preparations; Phase; Phase II/III Trial; Phase III Clinical Trials; Procedures; Publishing; Quality of life; Radiation; Radiation therapy; Recommendation; Request for Proposals; Research; Research Infrastructure; Risk; Risk Factors; Running; Safety; Science; Screening procedure; Site; Stem cells; Steroid therapy; Survivors; Therapeutic; Time; TimeLine; Tissues; Toddler; Toxic effect; Transplantation; U-Series Cooperative Agreements; Whole-Body Irradiation; Work; arm; body system; bone; chemotherapeutic agent; cohort; design; facial transplantation; functional outcomes; gastrointestinal; graft vs host disease; health related quality of life; high risk; improved; innovation; international center; medical complication; meetings; mortality; neglect; pilot trial; symposium; treatment effect; working group; young adult

DESCRIPTION (provided by applicant): As hematopoietic cell transplantation (HCT) has improved in frequency, safety and efficacy over the last two decades, the number of long-term survivors has markedly increased. Children undergoing this intense therapeutic modality are at high risk of a number of late toxicities. HCT-related late effects are a significant cause of morbidity and more importantly, mortality. HCT survivors who are <18yrs of age at the time of transplant face a risk of late mortality that is 17 fold higher than the general population. The majority of these non-relapse related late deaths can be attributed to infectious, cardiac and pulmonary causes. Risk factors for these and other causes of morbidity and mortality in HCT survivors must be identified so that 1) appropriate modifications in therapy can be made and 2) screening and/or intervention trials and health maintenance recommendations for HCT survivors can be developed. Due to the rarity of many of these adverse events, there is a need to follow large cohorts in order to arrive at meaningful associations. Multi-institutional studies allow one to achieve high numbers and also allow generalizability of findings, because they take into account the variability in the transplant practices at the various sites. In the last few years, significant improvements in the ability to perform multi-institutional pediatric HCT studies have combined with the development of a skilled group of pediatric experts in HCT late effects research. With expertise and infrastructure now available to allow this field to move into high-quality multi-center studies, we seek funding for a conference in Arlington, VA in April of 2011 aimed at defining the best questions, approaching them with the most innovative and informative methodologies, and coming to a consensus about how to prioritize the work and move forward. The conference organizing committee is composed of international experts in the fields of late effects and multicenter pediatric HCT research. Conference organizers have assembled a distinguished group of experts who have agreed to address the following areas: 1) methodological challenges in the study of late effects after HCT, 2) studies of biomarkers and/or genetic predisposition to late effects after HCT, and 3) approaches to the study of organ system dysfunction and health-related quality of life after HCT. Specific topics that will be addressed in item number three above include long-term post-HCT immunodeficiency, pulmonary, gastrointestinal, hepatic, renal, cardiovascular, neurocognitive and endocrine dysfunction, and quality of life and functional outcomes after HCT. The goal of the meeting will be to define priorities, establish working groups to move high-priority projects forward, set timelines to achieve established goals, and publish conference conclusions. This meeting will lay the foundation for a new generation of high-quality multi-center late effects studies that will eventually aid in defining approaches aimed at improving long-term outcomes in children undergoing HCT. PUBLIC HEALTH RELEVANCE: Because bone marrow transplantation occurs rarely in children, large studies that could allow us to better understand the seriousness and frequency of adverse medical complications that can occur several years after the transplant have not occurred. This proposal requests funding to support a conference attended by recognized experts in late complications after pediatric transplant therapy aimed at prioritizing topics, choosing the best approaches, and organizing specific efforts to plan studies. These studies will allow us to define aspects of the transplant procedure associated with increased risk, resulting in appropriate modifications of future transplant approaches and allowing the design of screening or intervention trials and health maintenance recommendations for transplant survivors.

描述（由申请人提供）：随着造血细胞移植（HCT）在过去二十年中在频率、安全性和有效性方面的改善，长期存活者的数量显著增加。儿童接受这种强烈的治疗方式是在一些晚期毒性的高风险。HCT相关的晚期效应是发病的重要原因，更重要的是，是死亡的重要原因。在移植时年龄<18岁的HCT幸存者面临的晚期死亡率风险是一般人群的17倍。这些非复发相关的晚期死亡中的大多数可归因于感染、心脏和肺部原因。必须确定HCT幸存者发病和死亡的这些和其他原因的风险因素，以便1）可以对治疗进行适当的修改，2）可以为HCT幸存者制定筛查和/或干预试验和健康维护建议。由于这些不良事件中的许多非常罕见，因此需要对大型队列进行随访，以得出有意义的关联。多机构研究允许实现高数字，也允许发现的普遍性，因为它们考虑到了不同地点移植实践的差异。在过去的几年里，进行多机构儿科HCT研究的能力有了显着的提高，同时也培养了一批熟练的HCT迟发效应研究儿科专家。随着专业知识和基础设施，现在可以让这一领域进入高质量的多中心研究，我们寻求资助的会议在阿灵顿，弗吉尼亚州在2011年4月，旨在定义最好的问题，接近他们与最创新和翔实的方法，并就如何优先工作和向前迈进达成共识。会议组委会由国际迟发效应和多中心儿科HCT研究领域的专家组成。会议组织者召集了一组杰出的专家，他们同意解决以下领域：1）HCT后晚期效应研究的方法学挑战，2）HCT后晚期效应的生物标志物和/或遗传易感性研究，以及3）HCT后器官系统功能障碍和健康相关生活质量研究的方法。将在上述第三项中讨论的具体主题包括HCT后长期免疫缺陷、肺、胃肠道、肝、肾、心血管、神经认知和内分泌功能障碍以及HCT后的生活质量和功能结局。会议的目标是确定优先事项，建立工作组以推进高优先项目，设定实现既定目标的时间表，并发表会议结论。本次会议将为新一代高质量的多中心迟发效应研究奠定基础，这些研究最终将有助于确定旨在改善接受HCT儿童长期结局的方法。 公共卫生关系：由于骨髓移植很少发生在儿童中，因此，可以让我们更好地了解移植后几年可能发生的不良医疗并发症的严重性和频率的大型研究尚未发生。该提案要求提供资金，以支持由公认的儿科移植治疗后晚期并发症专家参加的会议，旨在优先考虑主题，选择最佳方法，并组织具体的研究计划。这些研究将使我们能够确定与风险增加相关的移植程序的各个方面，从而对未来的移植方法进行适当的修改，并允许为移植幸存者设计筛选或干预试验和健康维护建议。